The purpose of this study is to assess the efficacy and safety of MK-8931 compared with placebo in the treatment of AD. The primary study hypotheses are that at least one MK-8931 dose is superior to placebo at 78 weeks of treatment with respect to change from Baseline as assessed using several cognitive scales.
For more information about this research study, please call Phyllis Vaughn at 404-728-6567 or email firstname.lastname@example.org.
Allan Levey, MD, PhD
This multinational study is using a placebo or the study drug, BAN240, to determine clinical efficacy and to explore the dose response of this drug. BAN2401 is an 18-month study in which drug/placebo is infused biweekly (once every 2 weeks). Subjects will be from 2 clinical subgroups: MCI due to Alzheimer's disease (AD) or mild Alzheimer's disease dementia. Effectiveness of drug treatment will be assessed using cognitive tests, as well as biological markers (MRI, PET, CSF, blood).
For more information about this research study, please call Gail Schwartz at 404-728-6395 or email email@example.com.
Emory Alzheimer's Disease Research Center Honor Research Registry
James Lah, MD, PhD
Clinical Core Leader, Emory Alzheimer's Disease Research Center
Felicia Goldstein, PhD
Clinical Core Co-Leader, Emory Alzheimer's Disease Research Center
The purpose of Honor is to have a group of volunteers who want to participate in future research studies on memory & thinking. By joining Honor you will learn about new research studies that are seeking volunteers. You will also receive our newsletter and invitations to educational events.
All Honor volunteers must have a “study partner” accompany them to their research visit. Your study partner will be asked questions about your memory and thinking. They will also be asked about your day to day functioning. A study partner is someone who has at least 10 hours of contact with you each week.
For more information about this research study, please call Letheshia Husbands at 404-728-6950 or email firstname.lastname@example.org .
Memory and Aging in African Americans and Caucasians
For more information about this research study, please call William Hu at 404-727-4174 or email email@example.com.
The purpose of this study is to establish the efficacy of Lu AE58054 as adjunctive therapy to donepezil (Aricept) for symptomatic treatment of patients with mild-to-moderate AD. Participants will take an oral dose of study drug daily for 6 months. Drug effectiveness will be determined by cognitive testing. If desired, participants can continue to receive study drug for an additional 6 months following study participation.